Biogen Idec Inc (BIIB) 322.06 $BIIB
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.12 (+1.98), BIIB: 322.06 (+0.81), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), JAZZ: 168.48 (-1.85), ALXN: 191.30 (+0.26), CELG: 105.75 (-1.66)
MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:40AM CST
MannKind's (MNKD) third-quarter 2014 loss came in at 9 cents per share, much narrower than the year-ago loss of 17 cents per share.
BIIB: 322.06 (+0.81), AMAG: 34.10 (+0.28), SNY: 45.49 (-0.29), MNKD: 5.92 (unch)
Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.30 (+0.60), MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), GERN: 2.68 (-0.12)
Is Biogen Idec (BIIB) a Great Growth Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:43AM CST
Biogen has been witnessing a positive trend in its current year earnings estimate and its long term growth rate is positive
BIIB: 322.06 (+0.81)
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), SGEN: 36.57 (-0.68), GILD: 109.72 (-0.26)
PharmaLeaders: Global Pharmaceutical Market Benchmark Report 2014: Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies
M2 - Mon Nov 03, 11:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/7gqdp8/pharmaleaders) has announced the addition of the "PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies" report to their offering. Pfizer was the Peer Group Benchmark Leader According to The authors's proprietary benchmarking analysis, Pfizer was the Global Pharmaceutical Market Benchmark Leader in 2013 with an overall score of 6.22. Pfizer's leadership status was the result of cost-cutting largely the headcount reductions from the divesture of its Animal Health business. This along with other rationalization measures, contributed to the company's income growth, and helped to drive Pfizer's net margin performance in 2013. Pharmaceutical Market Beginning to Show Signs of Stability According to Global Pharmaceutical Market Benchmark Report, the combined peer group revenue and average operating margin remained stable in 2013 when compared with 2012. Revenue from this peer group came in slightly lower by -0.2% to $718.7 billion. The average operating margin of the peer group was steady at 21.5%; however this was down by 90 basis points when compared to 2011. On the clinical side, R&D spending grew by $800 million to $111.9 billion in 2013, an increase of 0.7%. J&J was the growth leader in absolute dollars, increasing by $4.1 billion in 2013 driven by the company's immunology and oncology portfolios. Biogen Idec was the peer group revenue growth leader in 2013. Biogen's sales increased to $5.5 billion in 2013, a 25.7% rise from the $4.2 billion the company reported in 2012. Revenues soared as a result of Tysabri (natalizumab), the company's injectable monotherapy for treating relapsing forms of multiple sclerosis (MS), and the new oral MS drug Tecfidera (dimethyl fumarate). Sales of Tysabri grew 36.4% year-to-year from $1.1 billion in 2012 to $1.5 billion in 2013. The company also benefited from recognizing $876.1 million in new revenues from sales of Tecfidera despite having only been approved in March of 2013. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Global Pharmaceutical Market Dynamics - Sector Overview - Corporate Valuations - FDA Approved 27 Novel New Drugs in 2013 - New Approvals Drive Much Needed Value in the Pharmaceutical Market - Patent Cliff to Erode $65B in Sales by 2019 - Orphan Drugs: No Longer a Rare Opportunity - Regulatory Notes 4 Collaboration and Acquisition Strategies - Deal Values Soar Due to Shire Acquisition - Deep Dive: AbbVie Acquires Shire as the Threat of Humira Biosimilars Looms - M&A Analysis - Licensing and Partnerships 5 Financial Management - Global Pharmaceutical Market Competitive Landscape Assessment - Financial Management: Heat Map - Financial Performance Metrics 6 Expense Management - Global Pharmaceutical Market Competitive Landscape Assessment - Expense Management: Heat Map - Expense Performance Metrics 7 Therapy Franchise Analysis - Cardiovascular - CNS - Diabetes - Gastrointestinal - Hematology - Immunology - Infectious Disease - Oncology - Ophthalmology - Respiratory - Vaccines 8 Regional Analysis 9 Resource Management Strategies - Human Capital Management - Drugmakers Expand Manufacturing Capacity for Biologics - Firm Utilization: Heat Map - Firm Utilization Metrics - Capital Management: Heat Map - Capital Structure Metrics 10 Future Outlook - Global Pharmaceutical Market - Company Forecasts 11 Market Data - Global Pharmaceutical Market - Pipeline Analysis - Company Pipeline Profiles - Molecule Type 12 Appendix For more information visit http://www.researchandmarkets.com/research/7g...rmaleaders
BIIB: 322.06 (+0.81)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Mon Nov 03, 8:50AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 322.06 (+0.81), MNST: 100.04 (-1.19), ATI: 30.90 (-1.10), MON: 113.39 (-0.54), GMCR: 152.11 (+0.21), VMC: 63.50 (+1.10), EMR: 64.19 (-0.32), WDC: 100.00 (-0.75), VRSN: 58.79 (-0.77), URBN: 29.70 (-0.71), FSLR: 56.87 (-1.44), DE: 84.55 (-0.45), EXPE: 83.89 (-2.04), FLR: 63.77 (-2.01), FLS: 66.30 (-1.28), X: 36.57 (-2.57), ROK: 109.25 (-1.59), REGN: 372.39 (-22.87), MA: 83.99 (-0.14)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.61 (+0.32), BIIB: 322.06 (+0.81), AMGN: 160.41 (-1.15)
Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:30PM CDT
Alkermes' (ALKS) third-quarter 2014 loss came in at 25 cents per share, much wider than the loss of 5 cents reported in the year-ago quarter.
BIIB: 322.06 (+0.81), AZN: 73.36 (+0.80), ACOR: 34.78 (-0.40), ALKS: 50.36 (-0.52)
Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review
Thomson Reuters ONE - Fri Oct 31, 3:10PM CDT
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) of Elocta(TM) (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. The validation of the MAA initiates the EMA's review process.
BIIB: 322.06 (+0.81)
Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA(TM) (rFVIIIFc) Marketing Authorization Application for Review
Business Wire - Fri Oct 31, 3:05PM CDT
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of ELOCTA(TM) (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA's review process.
BIIB: 322.06 (+0.81)
Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:30PM CDT
Following the earnings release, shares of Affymetrix Inc. (AFFX) climbed 2.3% to close at $8.30 in the last session.
BIIB: 322.06 (+0.81), ILMN: 191.41 (-2.92), AMAG: 34.10 (+0.28), AFFX: 9.39 (+0.21)
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 322.06 (+0.81), INCY: 67.76 (-0.21), LLY: 67.17 (+0.63), NVS: 91.93 (+0.23)
Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:20PM CDT
Acorda (ACOR) which recently acquired Civitas Therapeutics, is working on reprioritizing its pipeline.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), NLNK: 32.60 (-0.01), ACOR: 34.78 (-0.40)
AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:57AM CDT
AMAG Pharmaceuticals (AMAG) reported third-quarter 2014 earnings of 6 cents per share as compared to a loss of 1 cent per share incurred in the year-ago quarter.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), AMAG: 34.10 (+0.28)
Today's Momo Momentum Stock To Watch: Biogen Idec (BIIB)
at The Street - Fri Oct 31, 8:50AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
BIIB: 322.06 (+0.81)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), INCY: 67.76 (-0.21), ILMN: 191.41 (-2.92)
The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF
PR Newswire - Fri Oct 31, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), Celgene (Nasdaq:CELG-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
BIIB: 322.06 (+0.81), BBH: 115.11 (-1.11), AMGN: 160.41 (-1.15), CELGZ: 3.62 (+0.02)
BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 322.06 (+0.81), AMAG: 34.10 (+0.28), BIND: 8.18 (+0.18), DYAX: 12.41 (+0.12)
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.79 (+0.01), TTWO: 25.92 (+0.09), BIIB: 322.06 (+0.81), GILD: 109.72 (-0.26), CRL: 64.12 (-0.31), REGN: 372.39 (-22.87), CELG: 105.75 (-1.66)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.12 (+1.98), BIIB: 322.06 (+0.81), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), JAZZ: 168.48 (-1.85), ALXN: 191.30 (+0.26), CELG: 105.75 (-1.66)
MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:40AM CST
MannKind's (MNKD) third-quarter 2014 loss came in at 9 cents per share, much narrower than the year-ago loss of 17 cents per share.
BIIB: 322.06 (+0.81), AMAG: 34.10 (+0.28), SNY: 45.49 (-0.29), MNKD: 5.92 (unch)
Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.30 (+0.60), MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), GERN: 2.68 (-0.12)
Is Biogen Idec (BIIB) a Great Growth Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:43AM CST
Biogen has been witnessing a positive trend in its current year earnings estimate and its long term growth rate is positive
BIIB: 322.06 (+0.81)
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), SGEN: 36.57 (-0.68), GILD: 109.72 (-0.26)
PharmaLeaders: Global Pharmaceutical Market Benchmark Report 2014: Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies
M2 - Mon Nov 03, 11:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/7gqdp8/pharmaleaders) has announced the addition of the "PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies" report to their offering. Pfizer was the Peer Group Benchmark Leader According to The authors's proprietary benchmarking analysis, Pfizer was the Global Pharmaceutical Market Benchmark Leader in 2013 with an overall score of 6.22. Pfizer's leadership status was the result of cost-cutting largely the headcount reductions from the divesture of its Animal Health business. This along with other rationalization measures, contributed to the company's income growth, and helped to drive Pfizer's net margin performance in 2013. Pharmaceutical Market Beginning to Show Signs of Stability According to Global Pharmaceutical Market Benchmark Report, the combined peer group revenue and average operating margin remained stable in 2013 when compared with 2012. Revenue from this peer group came in slightly lower by -0.2% to $718.7 billion. The average operating margin of the peer group was steady at 21.5%; however this was down by 90 basis points when compared to 2011. On the clinical side, R&D spending grew by $800 million to $111.9 billion in 2013, an increase of 0.7%. J&J was the growth leader in absolute dollars, increasing by $4.1 billion in 2013 driven by the company's immunology and oncology portfolios. Biogen Idec was the peer group revenue growth leader in 2013. Biogen's sales increased to $5.5 billion in 2013, a 25.7% rise from the $4.2 billion the company reported in 2012. Revenues soared as a result of Tysabri (natalizumab), the company's injectable monotherapy for treating relapsing forms of multiple sclerosis (MS), and the new oral MS drug Tecfidera (dimethyl fumarate). Sales of Tysabri grew 36.4% year-to-year from $1.1 billion in 2012 to $1.5 billion in 2013. The company also benefited from recognizing $876.1 million in new revenues from sales of Tecfidera despite having only been approved in March of 2013. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Global Pharmaceutical Market Dynamics - Sector Overview - Corporate Valuations - FDA Approved 27 Novel New Drugs in 2013 - New Approvals Drive Much Needed Value in the Pharmaceutical Market - Patent Cliff to Erode $65B in Sales by 2019 - Orphan Drugs: No Longer a Rare Opportunity - Regulatory Notes 4 Collaboration and Acquisition Strategies - Deal Values Soar Due to Shire Acquisition - Deep Dive: AbbVie Acquires Shire as the Threat of Humira Biosimilars Looms - M&A Analysis - Licensing and Partnerships 5 Financial Management - Global Pharmaceutical Market Competitive Landscape Assessment - Financial Management: Heat Map - Financial Performance Metrics 6 Expense Management - Global Pharmaceutical Market Competitive Landscape Assessment - Expense Management: Heat Map - Expense Performance Metrics 7 Therapy Franchise Analysis - Cardiovascular - CNS - Diabetes - Gastrointestinal - Hematology - Immunology - Infectious Disease - Oncology - Ophthalmology - Respiratory - Vaccines 8 Regional Analysis 9 Resource Management Strategies - Human Capital Management - Drugmakers Expand Manufacturing Capacity for Biologics - Firm Utilization: Heat Map - Firm Utilization Metrics - Capital Management: Heat Map - Capital Structure Metrics 10 Future Outlook - Global Pharmaceutical Market - Company Forecasts 11 Market Data - Global Pharmaceutical Market - Pipeline Analysis - Company Pipeline Profiles - Molecule Type 12 Appendix For more information visit http://www.researchandmarkets.com/research/7g...rmaleaders
BIIB: 322.06 (+0.81)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Mon Nov 03, 8:50AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 322.06 (+0.81), MNST: 100.04 (-1.19), ATI: 30.90 (-1.10), MON: 113.39 (-0.54), GMCR: 152.11 (+0.21), VMC: 63.50 (+1.10), EMR: 64.19 (-0.32), WDC: 100.00 (-0.75), VRSN: 58.79 (-0.77), URBN: 29.70 (-0.71), FSLR: 56.87 (-1.44), DE: 84.55 (-0.45), EXPE: 83.89 (-2.04), FLR: 63.77 (-2.01), FLS: 66.30 (-1.28), X: 36.57 (-2.57), ROK: 109.25 (-1.59), REGN: 372.39 (-22.87), MA: 83.99 (-0.14)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.61 (+0.32), BIIB: 322.06 (+0.81), AMGN: 160.41 (-1.15)
Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:30PM CDT
Alkermes' (ALKS) third-quarter 2014 loss came in at 25 cents per share, much wider than the loss of 5 cents reported in the year-ago quarter.
BIIB: 322.06 (+0.81), AZN: 73.36 (+0.80), ACOR: 34.78 (-0.40), ALKS: 50.36 (-0.52)
Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review
Thomson Reuters ONE - Fri Oct 31, 3:10PM CDT
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) of Elocta(TM) (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. The validation of the MAA initiates the EMA's review process.
BIIB: 322.06 (+0.81)
Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA(TM) (rFVIIIFc) Marketing Authorization Application for Review
Business Wire - Fri Oct 31, 3:05PM CDT
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of ELOCTA(TM) (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA's review process.
BIIB: 322.06 (+0.81)
Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:30PM CDT
Following the earnings release, shares of Affymetrix Inc. (AFFX) climbed 2.3% to close at $8.30 in the last session.
BIIB: 322.06 (+0.81), ILMN: 191.41 (-2.92), AMAG: 34.10 (+0.28), AFFX: 9.39 (+0.21)
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 322.06 (+0.81), INCY: 67.76 (-0.21), LLY: 67.17 (+0.63), NVS: 91.93 (+0.23)
Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:20PM CDT
Acorda (ACOR) which recently acquired Civitas Therapeutics, is working on reprioritizing its pipeline.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), NLNK: 32.60 (-0.01), ACOR: 34.78 (-0.40)
AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:57AM CDT
AMAG Pharmaceuticals (AMAG) reported third-quarter 2014 earnings of 6 cents per share as compared to a loss of 1 cent per share incurred in the year-ago quarter.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), AMAG: 34.10 (+0.28)
Today's Momo Momentum Stock To Watch: Biogen Idec (BIIB)
at The Street - Fri Oct 31, 8:50AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
BIIB: 322.06 (+0.81)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 103.83 (-1.57), BIIB: 322.06 (+0.81), INCY: 67.76 (-0.21), ILMN: 191.41 (-2.92)
The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF
PR Newswire - Fri Oct 31, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), Celgene (Nasdaq:CELG-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
BIIB: 322.06 (+0.81), BBH: 115.11 (-1.11), AMGN: 160.41 (-1.15), CELGZ: 3.62 (+0.02)
BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 322.06 (+0.81), AMAG: 34.10 (+0.28), BIND: 8.18 (+0.18), DYAX: 12.41 (+0.12)
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.79 (+0.01), TTWO: 25.92 (+0.09), BIIB: 322.06 (+0.81), GILD: 109.72 (-0.26), CRL: 64.12 (-0.31), REGN: 372.39 (-22.87), CELG: 105.75 (-1.66)
